REvisiting Lipids in REtinal Diseases: A Focused Review on Age-related Macular Degeneration and Diabetic Retinopathy

키워드

참고문헌 (100)

1. The Korean Society of Lipid and Atherosclerosis, "Dyslipidemia fact sheets in Korea 2018" (2018), The Korean Society of Lipid and Atherosclerosis
2. Yusuf S, "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries(the INTERHEART study) : case-control study", Lancet, 364, pp.937~952 (2004)
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), "Third report of the national cholesterol education program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panel III)final report", Circulation, 106, pp.3143~3421 (2002)
4. Grundy SM, "Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines", J Am Coll Cardiol, 44, pp.720~732 (2004)
5. Brunzell JD, "Lipoprotein management in patients with cardiometabolic risk : consensus statement from the American Diabetes Association and the American College of Cardiology Foundation", Diabetes Care, 31, pp.811~822 (2008)
6. Lee JW, "Expression and localization of sterol 27-hydroxylase(CYP27A1)in monkey retina", Exp Eye Res, 83, pp.465~469 (2006)
7. Mauch DH, "CNS synaptogenesis promoted by glia-derived cholesterol", Science, 294, pp.1354~1357 (2001)
8. Saher G, "Cholesterol : a novel regulatory role in myelin formation", Neuroscientist, 17, pp.79~93 (2011)
9. Brown MS, "Cholesterol feedback : from Schoenheimer's bottle to Scap's MELADL", J Lipid Res, 50, pp.S15~ (2009)
10. Wengrofsky P, "Dyslipidemia and its role in the pathogenesis of atherosclerotic cardiovascular disease: implications for evaluation and targets for treatment of dyslipidemia based on recent guidelines" (2019), IntechOpen
11. Hayreh SS, "Segmental nature of the choroidal vasculature", Br J Ophthalmol, 59, pp.631~648 (1975)
12. Fliesler SJ, "Retinal degenerative diseases: laboratory and therapeutic investigations", pp.481~489 (2010), Springer
13. Fliesler SJ, "The ins and outs of cholesterol in the vertebrate retina", J Lipid Res, 51, pp.3399~3413 (2010)
14. Elner VM, "Retinal pigment epithelial acid lipase activity and lipoprotein receptors : effects of dietary omega-3 fatty acids", Trans Am Ophthalmol Soc, 100, pp.301~338 (2002)
15. Tserentsoodol N, "Uptake of cholesterol by the retina occurs primarily via a low density lipoprotein receptor-mediated process", Mol Vis, 12, pp.1306~1318 (2006)
16. Duncan KG, "Expression of reverse cholesterol transport proteins ATP-binding cassette A1(ABCA1)and scavenger receptor BI(SR-BI)in the retina and retinal pigment epithelium", Br J Ophthalmol, 93, pp.1116~1120 (2009)
17. Wong WL, "Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040 : a systematic review and meta-analysis", Lancet Glob Health, 2, pp.e106~e116 (2014)
18. Resnikoff S, "Global data on visual impairment in the year 2002", Bull World Health Organ, 82, pp.844~851 (2004)
19. Coleman HR, "Age-related macular degeneration", Lancet, 372, pp.1835~1845 (2008)
20. Ferris FL 3rd, "Clinical classification of age-related macular degeneration", Ophthalmology, 120, pp.844~851 (2013)
21. Klein R, "The Wisconsin age-related maculopathy grading system", Ophthalmology, 98, pp.1128~1134 (1991)
22. Sarks SH, "Early drusen formation in the normal and aging eye and their relation to age related maculopathy : a clinicopathological study", Br J Ophthalmol, 83, pp.358~368 (1999)
23. Feeney-Burns L, "Age-related macular changes in humans over 90 years old", Am J Ophthalmol, 109, pp.265~278 (1990)
24. Green WR, "Age-related macular degeneration histopathologic studies : the 1992 Lorenz E. Zimmerman Lecture. 1992", Retina, 25, pp.1519~1535 (2005)
25. Löffler KU, "Basal linear deposit in the human macula", Graefes Arch Clin Exp Ophthalmol, 224, pp.493~501 (1986)
26. Rosa RH, "Clinicopathologic correlation of submacular membranectomy with retention of good vision in a patient with age-related macular degeneration", Arch Ophthalmol, 114, pp.480~487 (1996)
27. Sarks SH, "Ageing and degeneration in the macular region : a clinico-pathological study", Br J Ophthalmol, 60, pp.324~341 (1976)
28. Sarks SH, "Council lecture. Drusen and their relationship to senile macular degeneration", Aust J Ophthalmol, 8, pp.117~130 (1980)
29. van der Schaft TL, "Is basal laminar deposit unique for age-related macular degeneration?", Arch Ophthalmol, 109, pp.420~425 (1991)
30. van der Schaft TL, "Histologic features of the early stages of age-related macular degeneration. A statistical analysis", Ophthalmology, 99, pp.278~286 (1992)
31. Bressler NM, "Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration", Retina, 14, pp.130~142 (1994)
32. Curcio CA, "Basal linear deposit and large drusen are specific for early age-related maculopathy", Arch Ophthalmol, 117, pp.329~339 (1999)
33. Curcio CA, "Basal deposits and drusen in eyes with age-related maculopathy : evidence for solid lipid particles", Exp Eye Res, 80, pp.761~775 (2005)
34. Guyton JR, "The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy", Am J Pathol, 134, pp.705~717 (1989)
35. Small DM, "George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry", Arteriosclerosis, 8, pp.103~129 (1988)
36. Williams KJ, "The response-to-retention hypothesis of early atherogenesis", Arterioscler Thromb Vasc Biol, 15, pp.551~561 (1995)
37. Curcio CA, "Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins", Prog Retin Eye Res, 28, pp.393~422 (2009)
38. Olofsson SO, "Apolipoprotein B : a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis", J Intern Med, 258, pp.395~410 (2005)
39. Curcio CA, "The oil spill in ageing Bruch membrane", Br J Ophthalmol, 95, pp.1638~1645 (2011)
40. Dashti N, "Plasma apolipoproteins and risk for age related maculopathy", Br J Ophthalmol, 90, pp.1028~1033 (2006)
41. Klein R, "The relationship of atherosclerosis to the 10-year cumulative incidence of age-related macular degeneration : the Beaver Dam studies", Ophthalmology, 120, pp.1012~1019 (2013)
42. Risk factors for neovascular age-related macular degeneration, "The Eye Disease Case-Control Study Group", Arch Ophthalmol, 110, pp.1701~1708 (1992)
43. Reynolds R, "Serum lipid biomarkers and hepatic lipase gene associations with age-related macular degeneration", Ophthalmology, 117, pp.1989~1995 (2010)
44. van Leeuwen R, "Cholesterol and age-related macular degeneration : is there a link?", Am J Ophthalmol, 137, pp.750~752 (2004)
45. Klein R, "The association of cardiovascular disease with the long-term incidence of age-related maculopathy : the Beaver Dam eye study", Ophthalmology, 110, pp.636~643 (2003)
46. Delcourt C, "Associations of cardiovascular disease and its risk factors with age-related macular degeneration : the POLA study", Ophthalmic Epidemiol, 8, pp.237~249 (2001)
47. Hyman L, "Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group", Arch Ophthalmol, 118, pp.351~358 (2000)
48. Abalain JH, "Is age-related macular degeneration associated with serum lipoprotein and lipoparticle levels?", Clin Chim Acta, 326, pp.97~104 (2002)
49. Nowak M, "Changes in lipid metabolism in women with age-related macular degeneration", Clin Exp Med, 4, pp.183~187 (2005)
50. Yanai R, "Cytochrome P450-generated metabolites derived from ω-3 fatty acids attenuate neovascularization", Proc Natl Acad Sci U S A, 111, pp.9603~9608 (2014)
51. Hasegawa E, "Cytochrome P450 monooxygenase lipid metabolites are significant second messengers in the resolution of choroidal neovascularization", Proc Natl Acad Sci U S A, 114, pp.E7545~E7553 (2017)
52. Yanai R, "Attenuation of choroidal neovascularization by dietary intake of ω-3 long-chain polyunsaturated fatty acids and lutein in mice", PLoS One, 13, pp.e0196037~ (2018)
53. Laíns I, "Human plasma metabolomics in age-related macular degeneration : meta-analysis of two cohorts", Metabolites, 9, pp.127~ (2019)
54. Li M, "Analysis of the serum lipid profile in polypoidal choroidal vasculopathy", Sci Rep, 6, pp.38342~ (2016)
55. Jain MK, "Anti-inflammatory effects of statins : clinical evidence and basic mechanisms", Nat Rev Drug Discov, 4, pp.977~987 (2005)
56. Guymer RH, "HMG CoA reductase inhibitors(statins) : do they have a role in age-related macular degeneration?", Surv Ophthalmol, 50, pp.194~206 (2005)
57. Friedman E, "Update of the vascular model of AMD", Br J Ophthalmol, 88, pp.161~163 (2004)
58. Penfold PL, "Immunological and aetiological aspects of macular degeneration", Prog Retin Eye Res, 20, pp.385~414 (2001)
59. Curcio CA, "Subretinal drusenoid deposits in non-neovascular age-related macular degeneration : morphology, prevalence, topography, and biogenesis model", Retina, 33, pp.265~276 (2013)
60. Vavvas DG, "Regression of some high-risk features of age-related macular degeneration(AMD)in patients receiving intensive statin treatment", EBioMedicine, 5, pp.198~203 (2016)
61. Barbosa DT, "Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005–2008", Eye(Lond), 28, pp.472~480 (2014)
62. Guymer RH, "Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration", PLoS One, 8, pp.e83759~ (2013)
63. van Leeuwen R, "Is medication use associated with the incidence of early age-related maculopathy?", Pooled findings from 3 continents. Ophthalmology, 111, pp.1169~1175 (2004)
64. Klein R, "Relation of statin use to the 5-year incidence and progression of age-related maculopathy", Arch Ophthalmol, 121, pp.1151~1155 (2003)
65. Klein R, "Lipids, lipid genes, and incident age-related macular degeneration : the three continent age-related macular degeneration consortium", Am J Ophthalmol, 158, pp.513~524 (2014)
66. Cheung N, "Diabetic retinopathy", Lancet, 376, pp.124~136 (2010)
67. Wilkinson CP, "Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales", Ophthalmology, 110, pp.1677~1682 (2003)
68. Mitchell P, "Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema(DME)causing visual impairment : evidence from the RESTORE trial", Br J Ophthalmol, 96, pp.688~693 (2012)
69. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification, "ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group", Ophthalmology, 98, pp.786~806 (1991)
70. Zander E, "Maculopathy in patients with diabetes mellitus type 1 and type 2 : associations with risk factors", Br J Ophthalmol, 84, pp.871~876 (2000)
71. Diabetes Control and Complications Trial Research GroupNathan DM, "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus", N Engl J Med, 329, pp.977~986 (1993)
72. UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
73. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes : UKPDS 38. UK Prospective Diabetes Study Group", BMJ, 317, pp.703~713 (1998)
74. Esmann V, "Types of exudates in diabetic retinopathy", Acta Med Scand, 174, pp.375~384 (1963)
75. Ernest I, "Carbohydrate-rich, fat-poor diet in diabetes", Am J Med, 39, pp.594~600 (1965)
76. Brown GC, "Lipemic diabetic retinopathy", Ophthalmology, 91, pp.1490~1495 (1984)
77. Dodson PM, "Long-term follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy", Eye(Lond), 5, pp.699~703 (1991)
78. Cetin EN, "Association of serum lipid levels with diabetic retinopathy", Int J Ophthalmol, 6, pp.346~349 (2013)
79. Klein BE, "Serum lipids and proliferative diabetic retinopathy and macular edema in persons with long-term type 1 diabetes mellitus : the Wisconsin epidemiologic study of diabetic retinopathy", JAMA Ophthalmol, 133, pp.503~510 (2015)
80. Benarous R, "Differential association of serum lipids with diabetic retinopathy and diabetic macular edema", Invest Ophthalmol Vis Sci, 52, pp.7464~7469 (2011)
81. Raman R, "Influence of serum lipids on clinically significant versus nonclinically significant macular edema : SN-DREAMS report number 13", Ophthalmology, 117, pp.766~772 (2010)
82. Guerci B, "Severity of diabetic retinopathy is linked to lipoprotein(a)in type 1 diabetic patients", Diabetes Metab, 25, pp.412~418 (1999)
83. Li X, "Metabolomics study of diabetic retinopathy using gas chromatography-mass spectrometry : a comparison of stages and subtypes diagnosed by Western and Chinese medicine", Mol Biosyst, 7, pp.2228~2237 (2011)
84. Oliver MF, "Reduction of serum-lipid and uric-acid levels by an orally active androsterone", Lancet, 1, pp.1321~1323 (1962)
85. Duncan LJ, "A three-year trial of atromid therapy in exudative diabetic retinopathy", Diabetes, 17, pp.458~467 (1968)
86. Gaede P, "Effect of a multifactorial intervention on mortality in type 2 diabetes", N Engl J Med, 358, pp.580~591 (2008)
87. Nielsen SF, "Statin use before diabetes diagnosis and risk of microvascular disease : a nationwide nested matched study", Lancet Diabetes Endocrinol, 2, pp.894~900 (2014)
88. Denniston AK, "Cardiovascular therapies and their role in diabetic eye disease", Diabet Med, 22, pp.665~666 (2005)
89. Liinamaa MJ, "High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins", Ann Med, 40, pp.209~214 (2008)
90. Zhang J, "Association of statin use with the risk of developing diabetic retinopathy", Arch Ophthalmol, 125, pp.1096~1099 (2007)
91. Panagiotoglou TD, "Atorvastatin for diabetic macular edema in patients with diabetes mellitus and elevated serum cholesterol", Ophthalmic Surg Lasers Imaging, 41, pp.316~322 (2010)
92. Sen K, "Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia", Diabetes Res Clin Pract, 56, pp.1~11 (2002)
93. Keech AC, "Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study) : a randomised controlled trial", Lancet, 370, pp.1687~1697 (2007)
94. Chew EY, "Effects of medical therapies on retinopathy progression in type 2 diabetes", N Engl J Med, 363, pp.233~244 (2010)
95. Narang S, "Atorvastatin in clinically-significant macular edema in diabetics with a normal lipid profile", Nepal J Ophthalmol, 4, pp.23~28 (2012)
96. Colhoun HM, "Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS) : multicentre randomised placebo-controlled trial", Lancet, 364, pp.685~696 (2004)
97. Fried LF, "Lipid modulation in insulin-dependent diabetes mellitus : effect on microvascular outcomes", J Diabetes Complications, 15, pp.113~119 (2001)
98. Chew EY, "Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study(ETDRS)report 22", Arch Ophthalmol, 114, pp.1079~1084 (1996)
99. Miljanovic B, "A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes", Diabetes, 53, pp.2883~2892 (2004)
100. Klein BE, "Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration?", Am J Ophthalmol, 128, pp.652~654 (1999)

관련 논문AI추천